RNA Therapeutics for Wound Healing via Local Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wound healing, including recombinant growth factors and gene therapy, face challenges such as short half-life, low bioavailability, enzymatic inactivation, and the need for carrier molecules, and there is a need for novel therapeutics to effectively promote acute and chronic wound healing.
Innovation Solution
The use of RNA encoding therapeutic proteins like collagenases, growth factors, cytokines, chaperones, or signal transduction inhibitors, which are administered to cells or patients to promote wound healing by encoding specific coding sequences that facilitate effective expression and tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant growth factors are used to promote wound healing, then wound healing is improved, but the treatment has short half-life and low bioavailability
Solution Approach 1:
The patent uses mRNA copies of growth factor genes to instruct cells to produce therapeutic proteins locally. Instead of administering protein directly (which has short half-life), the mRNA copy enables sustained endogenous production of growth factors at the wound site, effectively extending the duration of action while maintaining therapeutic effectiveness.
2Reliability
If recombinant growth factors are used to promote wound healing, then wound healing is improved, but enzymatic inactivation occurs
Solution Approach 1:
By transferring the genetic code (mRNA copy) rather than the protein itself, the system avoids enzymatic degradation of the therapeutic protein. The mRNA is protected by lipid nanoparticles and instructs local cells to produce the growth factor, bypassing the vulnerability of exogenous proteins to enzymatic inactivation.
3Reliability
If gene therapy is used to promote wound healing, then wound healing is improved, but carrier molecules are required
Solution Approach 1:
The patent uses lipid nanoparticles as intermediary carriers to deliver mRNA to target cells. These biodegradable lipid structures protect the mRNA from degradation, facilitate cellular uptake, and enable controlled release of the genetic material at the wound site, simplifying the overall therapy compared to viral vector systems.
Data Source
AI summary
The present invention relates to an RNA encoding a therapeutic protein, in particular a collagenase, growth factor, cytokine, receptor, chaperone or signal transduction inhibitor. In particular, the present invention relates to RNA suitable for treatment of wounds, specifically for promoting wound healing. The present invention concerns such RNA as well as pharmaceutical compositions and kits and combinations comprising the RNA. Furthermore, the present invention relates to the RNA, pharmaceutical compositions, kits as disclosed herein for use in the treatment of wounds, specifically for promoting wound healing.